Treatment of complicated and uncomplicated urinary tract infections caused by
susceptible gram-negative and gram-positive bacteria and uncomplicated urethral
or cervical gonorrhea due to N. gonorrhoeae
Hypersensitivity to enoxacin, any component, or other
Use with caution in patients with a history of convulsions or epilepsy, renal
dysfunction, psychosis, elevated intracranial pressure, prepubertal children,
and pregnancy; nalidixic acid and ciprofloxacin (related compounds) have been
associated with erosions of the cartilage in weight-bearing joints and other
signs of arthropathy in immature animals and children; similar precautions are
advised for enoxacin although no data is available; has rarely caused ruptured
tendons (discontinue immediately with signs of inflammation or tendon
1% to 10%:
Central nervous system: Dizziness (<3%), headache (<2%), vertigo (3%)
Gastrointestinal: Nausea (2.9%), vomiting (6% to 9%), abdominal pain (1% to
2%), diarrhea (1% to 2%)
<1%: Palpitations, syncope, edema, restlessness, confusion, seizures,
fatigue, drowsiness, depression, insomnia, confusion, chills, fever, rash,
photosensitivity, pruritus, exfoliative dermatitis, hypo/hyperkalemia, GI
bleeding, dyspepsia, xerostomia, constipation, flatulence, anorexia, vaginitis,
anemia, leukopenia, eosinophilia, leukocytosis, increased liver enzymes, tremor,
arthralgia, ruptured tendons, paresthesias, visual disturbances, increased serum
creatinine/BUN, acute renal failure, proteinuria
Symptoms of overdose include acute renal failure, seizures
GI decontamination and supportive care; diazepam for seizures; not removed by
peritoneal or hemodialysis
CYP1A2 enzyme inhibitor
Increased toxicity/levels of warfarin, cyclosporine, digoxin, caffeine, and
theophylline with enoxacin
Increased levels of enoxacin with cimetidine, probenecid
Inhibits DNA-gyrase in susceptible organisms; inhibits relaxation of
supercoiled DNA and promotes breakage of double-stranded
Distribution: Penetrates well into tissues and body secretions
Half-life: 3-6 hours (average)
Elimination: Primarily in urine, however, significant drug concentrations are
achieved in feces
Cystitis: 200 mg twice daily for 7 days
Uncomplicated gonorrhea: 400 mg as single dose
Dosing adjustment in renal impairment: Clcr <50
mL/minute: Administer 50% of dose
|Mental Health: Effects
on Mental Status|
May cause dizziness; rarely may cause confusion, insomnia, or drowsiness;
quinolones reported to cause restlessness, hallucinations, euphoria, depression,
panic, and paranoia
Effects on Psychiatric
Rarely causes leukopenia; use caution with clozapine and
|Dental Health: Local
No information available to require special precautions
Effects on Dental Treatment|
No effects or complications reported
Take as prescribed and for as long as directed. Take on an empty stomach (1
hour prior to or after meals). Do not use antacids within 2 hours of medication.
Maintain adequate hydration (2-3 L/day of fluids unless instructed to restrict
fluid intake). You may experience stomach discomfort (eat small, frequent meals)
and dizziness or blurred vision (use caution when driving). May cause
photosensitivity (use sunscreen, wear protective clothing and eyewear, and avoid
direct sunlight). Report skin rash; visual changes; severe gastric upset;
weakness; pain, inflammation, or rupture of tendon; or signs or symptoms of
opportunistic infection (eg, white spots or sores in mouth or perineal area,
itching or vaginal discharge, unhealed sores, fever).
Pregnancy/breast-feeding precautions: Inform prescriber if you are or intend
to be pregnant. Do not breast-feed.
Hold antacids for 3-4 hours before or after administering; administer on an
empty stomach; encourage fluids
Patients receiving concurrent enoxacin and theophylline should have serum
levels of theophylline monitored
Tablet: 200 mg, 400 mg
Dobbs BR, Gazeley LR, Campbell AJ, et al,
"The Effect of Age on the Pharmacokinetics of Enoxacin," Eur J Clin
Pharmacol, 1987, 33(1):101-4.
Hooper DC and Wolfson JS, "Fluoroquinolone Antimicrobial Agents," N Engl J
Med, 1991, 324(6):384-94.
Izu R, Gardeazabal J, Gonzalez M, et al,
"Enoxacin-Induced Photosensitivity: Study of Two Cases," Photodermatol
Photoimmunol Photomed, 1992, 9(2):86-8.
Lomaestro BM and Bailie GR, "Quinolone-Cation Interactions: A Review,"
DICP, 1991, 25(11):1249-58.
Patel SS and Spencer CM,
"Enoxacin: A Reappraisal of Its Clinical Efficacy in the Treatment of Genitourinary Tract Infections,"
Drugs, 1996, 51(1):137-60.
Stein GE, "The 4-Quinolone Antibiotics: Past, Present, and Future,"
Pharmacotherapy, 1988, 8(6):301-14.
Szarfman A, Chen M, and Blum MD,
"More on Fluoroquinolone Antibiotics and Tendon Rupture," N Engl J Med,
Walker RC and Wright AJ, "The Fluoroquinolones," Mayo Clin Proc, 1991,
Wise R, Baker SL, Misra M, et al,
"The Pharmacokinetics of Enoxacin in Elderly Patients," J Antimicrob
Chemother, 1987, 19(3):343-50.
Copyright © 1978-2000 Lexi-Comp Inc. All Rights Reserved